124 related articles for article (PubMed ID: 9257113)
21. The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas.
Ohneda A; Ohneda K; Ohneda M; Koizumi F; Ohashi S; Kawai K; Suzuki S
Tohoku J Exp Med; 1991 Nov; 165(3):209-21. PubMed ID: 1807008
[TBL] [Abstract][Full Text] [Related]
22. Absence of a memory effect for the insulinotropic action of glucagon-like peptide 1 (GLP-1) in healthy volunteers.
Meier S; Hücking K; Ritzel R; Holst JJ; Schmiegel WH; Nauck MA
Horm Metab Res; 2003 Sep; 35(9):551-6. PubMed ID: 14517773
[TBL] [Abstract][Full Text] [Related]
23. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
24. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
25. [The entero-insular axis: the new incretin candidate glucagon-like peptide-1(7-36)amide (GLP-1(7-36))amide].
Göke R; Göke B; Richter G; Arnold R
Z Gastroenterol; 1988 Nov; 26(11):715-9. PubMed ID: 2849249
[TBL] [Abstract][Full Text] [Related]
26. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
27. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
Ahrén B; Hughes TE
Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
[TBL] [Abstract][Full Text] [Related]
29. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide.
Heller RS; Aponte GW
Am J Physiol; 1995 Dec; 269(6 Pt 1):G852-60. PubMed ID: 8572216
[TBL] [Abstract][Full Text] [Related]
30. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
[TBL] [Abstract][Full Text] [Related]
31. Glucose-dependent stimulatory effect of glucagon-like peptide 1(7-36) amide on the electrical activity of pancreatic beta-cells recorded in vivo.
Fernandez J; Valdeolmillos M
Diabetes; 1999 Apr; 48(4):754-7. PubMed ID: 10102691
[TBL] [Abstract][Full Text] [Related]
32. The effect of gastrin-releasing peptide on the endocrine pancreas.
McDonald TJ; Houghton P; Challis JR; Hramiak IM
Ann N Y Acad Sci; 1988; 547():242-54. PubMed ID: 3071222
[TBL] [Abstract][Full Text] [Related]
33. Role of nitric oxide mechanisms in gastric emptying of, and the blood pressure and glycemic responses to, oral glucose in healthy older subjects.
Gentilcore D; Visvanathan R; Russo A; Chaikomin R; Stevens JE; Wishart JM; Tonkin A; Horowitz M; Jones KL
Am J Physiol Gastrointest Liver Physiol; 2005 Jun; 288(6):G1227-32. PubMed ID: 15691867
[TBL] [Abstract][Full Text] [Related]
34. Effects of truncated glucagon-like peptide-1 on pancreatic hormone release in normal conscious dogs.
Kawai K; Suzuki S; Ohashi S; Mukai H; Murayma Y; Yamashita K
Acta Endocrinol (Copenh); 1990 Dec; 123(6):661-7. PubMed ID: 2284891
[TBL] [Abstract][Full Text] [Related]
35. Ghrelin activates neuronal constitutive nitric oxide synthase in pancreatic islet cells while inhibiting insulin release and stimulating glucagon release.
Qader SS; Lundquist I; Ekelund M; Håkanson R; Salehi A
Regul Pept; 2005 May; 128(1):51-6. PubMed ID: 15721487
[TBL] [Abstract][Full Text] [Related]
36. The effect of gastrin-releasing peptide on the endocrine pancreas.
Knuhtsen S; Holst JJ; Schwartz TW; Jensen SL; Nielsen OV
Regul Pept; 1987 May; 17(5):269-76. PubMed ID: 2885899
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients.
Herrmann C; Göke R; Richter G; Fehmann HC; Arnold R; Göke B
Digestion; 1995; 56(2):117-26. PubMed ID: 7750665
[TBL] [Abstract][Full Text] [Related]
38. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
40. Role of endogenous nitric oxide in the control of exocrine and endocrine pancreatic secretion.
Bilski J; Konturek SJ; Bielański W
J Physiol Pharmacol; 1995 Dec; 46(4):447-62. PubMed ID: 8770789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
